Seeking Alpha


Send Message
View as an RSS Feed
View dharma_bear's Comments BY TICKER:
Latest  |  Highest rated
  • Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side [View article]
    This part is wrong:
    "companies with compelling late-stage results tend to push them out in a matter of days following the cessation of a trial, not weeks." It takes 6-8 weeks after the trigger event to analyze and report the data. Can you link to an example to the contrary?

    Also from the company's report on their P2 in progress for previously untreated AML: " 30 patients were evaluable for response; 13 patients (43%) achieved complete response (NYSE:CR), 6 patients (20%) achieved CR with incomplete platelet recovery (CRp), and 3 patients (10%) achieved CR with incomplete peripheral blood count recovery (CRi), for an overall response rate of 73%." Agreed that the current P3 will not be as good, but do you really want to be short if they report a >25% increase in OS? With the October straddle priced at >$6 this could easily gap up more than that.
    Aug 28 04:54 PM | Likes Like |Link to Comment
  • China Finance Online: Shares Soar On Over-Hyped Deal, More Questions Than Answers [View article]
    The actual text of the PR: "launched China's first **independent** web-based securities trading platform". There are 117 stockbrokers in the country of China. Do any of these NOT have web-based trading platforms? What is "independent" supposed to mean?
    Aug 21 09:25 AM | 1 Like Like |Link to Comment
  • 2 Tactical Municipal Bond Strategies For Non-Qualified Retirement Portfolios [View article]
    Very nice work. It looks like this asset class is subject to periodic panic selling and a strategy could be built around that - pick the worst performer, buy when it stops making new lows and sell when it recovers. One would need to be careful to avoid macro shocks such as started in early June 2013.
    Jul 6 08:46 AM | Likes Like |Link to Comment
  • Dynex Capital Pays Strong Dividend, Offers Positive Outlook For Second Half Of 2014 [View article]
    This report a waste of electrons.
    Jul 2 04:50 PM | Likes Like |Link to Comment
  • An Update Of Uni-Pixel's Production Status [View article]
    Selling due to getting deleted from the Russell index will be going on next week. Interesting to see what price it takes for buyers to step up, but it won't be me. Thanks for the article.
    Jun 21 06:04 PM | Likes Like |Link to Comment
  • New Gold Discovery At San Miguel May Make Shorts Cover [View article]
    Based on the most recent 10-q they would have burned through all their cash by now, but for:
    "As of April 30, the Company sold 2,011,799 shares for gross proceeds of $2,113,585 pursuant to a Controlled Equity Offering Sales Agreement entered into with Cantor Fitzgerald & Co. on April 11, 2014."
    which is not going to last very long. Looks like a hand to mouth existence. Do they have any plan for better financing?
    Jun 21 05:31 PM | Likes Like |Link to Comment
  • Medallion Financial: Hail This High Yield [View article]
    Down 11% since your comment. That's 1 1/2 years' dividends. No guarantee it won't fall further. Not what you want for a high yielder. Lots of other opportunities.
    Jun 17 02:14 PM | 1 Like Like |Link to Comment
  • Genie Energy - Arbitrage Play With 10% Return In A Month [View article]
    This stock is scheduled for deletion from the Russell 2000. This event takes place at the end of the month which creates selling pressure.
    Jun 15 04:37 PM | Likes Like |Link to Comment
  • General Finance Corp: A Truly Undiscovered Gem With Significant Upside [View article]
    The ratio market cap/EBITDA is not a good measure because it inflates the denominator by excluding the interest on the debt, and deflates the numerator by failing to include the debt used to generate the EBITDA. The correct measure is EV/EBITDA, where EV = enterprise value = market cap+debt, or, alternatively, market cap/earnings, a.k.a. P/E. It would be great to see a revision of the article with the corrected measure.

    That said it does appear to be undervalued.
    Mar 29 12:54 PM | Likes Like |Link to Comment
  • Kona Grill, Inc. Lays Its Organic Growth And Expansion On The Table [View article]
    Is this their first expansion in recent history? Sales have been flat since late 2011. The price is up so much last 6 months it would seem to have discounted this expansion and more.
    Mar 26 06:30 PM | Likes Like |Link to Comment
  • Zeiher Study Likely Predicts The Outcome Of NeoStem's AMR-001 Trial [View article]
    Here's a better link:

    "in the BMC (bone marrow-derived cells) group, only the basal (P = 0.02) and the stromal cell-derived factor-1-induced (P = 0.05) migratory capacity of the administered BMC were associated with improved clinical outcome.
    In patients of the REPAIR-AMI trial, established clinical parameters are associated with adverse outcome at 5 years exclusively in the placebo group, whereas the migratory capacity of the administered BMC determines event-free survival in the BMC-treated patients. These data disclose a potency-effect relationship between cell therapy and long-term outcome in patients with AMI."

    Can a knowledgeable person compare this to the NBS trial?
    Mar 25 05:46 PM | Likes Like |Link to Comment
  • NeoStem Should Make Investors Very Happy In The Near Future [View article]
    I think NBS is interesting and considering a buy, however, silly statements about the financials do not serve you:
    >17,053% growth in revenue
    Off of a miniscule base. So what.
    >capital expenditure has decreased by $13 million since 2010.
    By your own figures negative cash flow is at record levels. The company needs to fund it and regardless of whether it is due to capex or opex.

    Speaking of funding, NBS has been issuing secondaries every 4 months or so, and they are overdue. Perhaps investors are better served waiting for the next round.
    Mar 25 04:58 PM | Likes Like |Link to Comment
  • AG Mortgage Preferred Stocks: Opportunities And Risks [View article]
    This article was designated at your website as a showcase of your abilities. I came here to see if I wanted to subscribe. Your analysis of credit quality was non-existent. What set of extreme adverse circumstances could impair the principal of this issue? I learned more about this by reading the comments. Is this issue perpetual? What is the interest rate sensitivity?
    Feb 14 04:42 PM | Likes Like |Link to Comment
  • Bear Raid On Progenics Pharmaceuticals Provides Opportune Buy [View article]
    This treatment causes leukopenia (reduced WBCs), so sepsis is a real and present danger, and in some cases, a likely consequence of the treatment. PGNX backed off from a higher dose in Phase I due to a patient death from sepsis in that study. It is also true that these are end of the line patients with no treatment alternatives. However, this will always be a last resort at best.
    Feb 10 02:48 PM | Likes Like |Link to Comment
  • BioScrip: A Hammered Stock But A Potential Buy Under $10 [View article]
    This stock has traded at a P/S multiple ranging from .1-.3 for many years, back at a time when they were showing profits instead of losses.
    Jan 28 03:57 PM | Likes Like |Link to Comment